Nanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management
|
|
- Alexina Mitchell
- 6 years ago
- Views:
Transcription
1 Nanotechnology: A Brief History and Its Convergence with Medicine Weston Daniel, PhD Director of Program Management
2 Outline Introduction The Nanoscale Applications Realization of a Vision
3 There s Plenty of Room at the Bottom I am not afraid to consider the final question as to whether, ultimately in the great future we can arrange the atoms the way we want; the very atoms, all the way down! -- Richard Feynman December 29, 1959 California Institute of Technology
4 Historical Significance of Nanomaterials s 2000s Observation of Nanoscale Phenomena Early Understanding of the Nanoscale/ Era of Miniaturization Rational Design and Manipulation of Nanoscale Objects
5 How Small is a Nanometer? 50 nm DNA (width) ~2 nm Gold Nanoparticles 2-80 nm Silver Nanoprism 5-75 nm Flu Virus 100 nm
6 Tools for Studying Nanoparticles Scanning Electron Microscope (SEM) Transmission Electron Microscope (TEM) Scanning Tunneling Microscope (STM) Au (100) Surface
7 Nanotechnology: An Ambiguous Term 1. Developing tools for making, characterizing, and manipulating materials on the nanometer (nm) length scale 2. Determining the chemical and physical consequences of miniaturization.
8 On the Nanoscale, Size, Shape, as Well as Composition Matter Rayleigh Light Scattering of Nanoparticles Ag Nanoprisms ~100 nm Au Spheres ~100 nm Au Spheres ~50 nm Ag Spheres ~100 nm Ag Spheres ~80 nm Ag Spheres ~40 nm 200 nm 200nm (the same for all the images)
9 Nanotechnology: An Ambiguous Term 1. Developing tools for making, characterizing, and manipulating materials on the nanometer (nm) length scale 2. Determining the chemical and physical consequences of miniaturization. 3. Exploiting the ability to miniaturize and its consequences in the development of new technology.
10 Nanotechnology: Areas of Impact Electronics Security and Defense Nanotechnology Medicine Clean Water and the Environment Energy
11 Where is Nanotechnology Now? Sunscreens Sporting Goods Sunscreen chalky (war-paint) zinc creams replaced by clear creams with nano-sized zinc oxide particles Home Appliances High-strength carbon composite materials Fabrics Protection from bacteria using thin film coatings and silver particle embedded plastics Stain protection & spill protection - by Nano-Tex
12 Where is Nanotechnology Now? Disease Detection Bone Replacement Integrated Circuits FDA-cleared Verigene System for detection of blood stream infections Nanocrystalline bone graft scaffold provides high surface area for cell growth Wafer-scale production of transistors at Intel
13 Where is Nanotechnology Now? ~100 nm
14 Nanotechnology: Areas of Impact Electronics Security and Defense Nanotechnology Medicine Clean Water and the Environment Energy
15 Nanotechnology: Areas of Impact Electronics Security and Defense Nanotechnology Medicine Clean Water and the Environment Energy
16 The Convergence of Nanoscience and Nanotechnology with Medicine Diagnostics Imaging Therapeutics FDA-Cleared Verigene System Animals Cells AuroLase Therapy (Nanoshells) High sensitivity and selectivity molecular diagnostics In vivo imaging materials (better contrast, theranostic capabilities) Tools for genetically manipulating cells and making intracellular measurements New and potentially better approaches to drug delivery and gene therapy
17
18 SNA Technology: A Powerful Platform for Nucleic Acid Therapeutics Proprietary, 3D SNAs treat diseases at genetic origins Unlock the potential of nucleic acid therapeutics in large, new therapeutic areas Address targets inaccessible to small molecules and antibodies Potential applications in eye, skin, lung, GI tract, brain, and hematological and solid cancers Cross biological barriers (e.g. skin) when administered locally Produce powerful anti-tumor immune response in mouse models Well protected with IP; sit well outside alternate approaches AST-005, topical anti-tnf for psoriasis (Phase 1 trial expected in 1H 2016) Preclinical data demonstrate TNF knockdown in human psoriatic skin Safety, efficacy and biomarker readouts expected in 2H 2016 Large unmet medical need in mild / moderate psoriasis AST-008 for immuno-oncology (Regulatory filing expected in 2H 2016) Enhanced efficacy against variety of cancers in mouse models in combination with certain checkpoint inhibitors 18
19 The Spherical Nucleic Acid (SNA) Linear DNA Oligonucleotides can be antisense (Science, 2006), sirna (JACS, 2009), mirna (Genes and Dev., 2015) or immuno-modulatory (PNAS, 2015), Amenable to a variety of attachment chemistries and oligonucleotide modifications SNA 19
20 SNA Platform Represents the Next Generation of Nucleic Acid Therapeutics Important Biological Properties Existing Technology SNAs Amenable to multiple gene regulation approaches Effective against intracellular targets Entry via receptors found primarily on liver cells Entry via receptors found ubiquitously, including liver Can readily enter cells and organs outside the liver No need for encapsulation No need for complexation Effective for immuno-oncology applications Novel IP 20
21 Gene Regulatory SNAs
22 Lead Development Programs Development Stage Therapeutic Candidate Indication Research In Vivo Optimization Preclinical Development Phase 1 Milestones Gene Regulation AST-005 Targeting TNF SNA Targeting IL17RA SNA Targeting IL4RA Mild to moderate psoriasis Inflammatory disorders Inflammatory disorders CTA submission 2H 2015 Phase 1 readout 2H 2016 Immuno-Oncology AST-008 with Checkpoint Inhibitor AST-008 with Antigen AST-008 Monotherapy Solid tumors Solid tumors Solid tumors For one or more of these approaches: IND submission 2H 2016 Phase 1 initiation 1H
23 AST-005 Preclinical Data Demonstrated target engagement and mechanism of action in viable psoriatic human skin Demonstrated uptake into viable human skin Demonstrated efficacy in mouse models of the disease SNA SNAs Enter Human Psoriatic Skin After Topical Application Epidermis (SNA in red) Negative Control 0% Knockdown in Psoriatic Human Skin AST ± 14% 23
24 AST-005 Reverses Psoriasis in Mouse Model of the Disease No SNA TNF SNAs 24
25 AST-005 First in Human Study Evaluates Safety, Efficacy, and Biomarkers in Patients Quickly and Efficiently Objectives Doses Safety, efficacy, biomarkers AST-005 gel (at three strengths), positive and negative controls Endpoints Safety and tolerability Efficacy as measured by inflammatory infiltrate thickness Biomarker knockdown (TNF) Timing Initiation to report 6 months 25
26 Mild to Moderate Psoriasis is an Unmet Medical Need Parameters Competitive Advantage Development Advantage Prevalence Topical Psoriasis Market Key Information SNAs penetrate into skin when applied topically and reduce TNF mrna level Rapid clinical trials Up to 7.5 MM Americans have psoriasis $850 MM worldwide (2008) Distribution of Psoriasis Severity Moderate to Severe Mild to Moderate 80% 20% Market size: Nat. Rev. Drug Discov. 8,
27 Immuno-oncology SNAs
28 AST-008 Increases Efficacy of Checkpoint Inhibitors in a Number of Mouse Cancer Models Checkpoint inhibitors remove immune suppressive cancer signals, allowing for latent immune response to clear the tumor ( brake off ) 70-80% of tumors are non-inflamed and have little to no latent immune response AST-008 increases the magnitude and intensity of the latent immune response ( gas on ) 28
29 AST-008 Potentiates Activity of anti-pd-1 Antibodies in PD-1 Resistant Tumors and Confers Adaptive Immunity (Mouse Breast Cancer Model) Tumor Volume (mm 3 ) AST-008 Anti-PD-1 Vehicle Anti-PD -1 Anti-PD-1 + Linear Oligo Anti-PD-1 + AST-008 Naive Mice ** Days Re-challenge * = p < 0.05; ** = p < 0.01 * Over 90% reduction in tumor volume in combination group compared to PD-1 antibody alone AST-008 resulted in an 88% average decrease in tumor volume compared to linear oligonucleotides 7 out of 8 mice in the combination group were tumor free Mice treated with AST-008 and checkpoint inhibitors resist second tumor challenge without additional therapy AST-008: 0.8 mg/kg/dose; Anti-PD-1: 10 mg/kg/dose n=8 29
30 AST-008 Synergizes with anti-ctla4 Antibody (Mouse Colorectal Cancer Model) Tumor Volume Survival AST-008 Anti-CTLA4 Over 75% reduction in tumor volume in combination group versus anti-ctla4 Over 42% increase in median survival in combination group versus anti-ctla4 (52.5 days vs 37 days) AST-008: 0.3 mg/kg/dose; Anti-CTLA4: 10 mg/kg/dose; n=10 30
31 AST-008 Reduces Tumor Growth and Increases Survival in Orthotopic Mouse Bladder Cancer Model AST-008 As a Monotherapy in Sub-Q model AST-008 With Checkpoint Inhibitor in Orthotopic model AST-008 BCG AST-008 decreases tumor volume versus vehicle and a standard of care, BCG AST-008: 2 mg/kg/dose BCG: 1.35 mg/dose n=8 AST-008 Anti-PD-1 Increased in overall survival in combination group versus anti-pd-1 antibody alone AST-008: 2 mg/kg/dose Anti-PD-1: 10 mg/kg/dose n=13 *** p <
32 AST-008 and a-pd-1 Combination Groups Reduces Tumor Growth in B16F10 Melanoma Model Mean Tumor Vol. (mm 3 ) AST-008 Anti-PD-1 V eh icle Anti-PD -1 AS T-008 AST Anti-PD Days ** ** = p < % reduction in tumor volume in AST-008 and combination groups compared to PD-1 antibody alone At day 39, 10 out of 10 mice in the AST-008 and a-pd-1 combination group alive; 8 out 10 for AST-008 alone; 3 mice alive in anti-pd-1 alone AST-008: 0.8 mg/kg/dose; Anti-PD-1: 10 mg/kg/dose n=10 32
33 SNA Technology: A Powerful Platform for Nucleic Acid Therapeutics Proprietary, 3D SNAs treat diseases at genetic origins Unlock the potential of nucleic acid therapeutics in large, new therapeutic areas Address targets inaccessible to small molecules and antibodies Potential applications in eye, skin, lung, GI tract, brain, and hematological and solid cancers Cross biological barriers (e.g. skin) when administered locally Produce powerful anti-tumor immune response in mouse models Well protected with IP; sit well outside alternate approaches AST-005, topical anti-tnf for psoriasis (Phase 1 trial expected in 1H 2016) Preclinical data demonstrate TNF knockdown in human psoriatic skin Safety, efficacy and biomarker readouts expected in 2H 2016 Large unmet medical need in mild / moderate psoriasis AST-008 for immuno-oncology (Regulatory filing expected in 2H 2016) Enhanced efficacy against variety of cancers in mouse models in combination with certain checkpoint inhibitors 33
34 Realization of a Vision Image courtesy of the Mirkin lab, Northwestern University
NSE Grantees Meeting December 2015
NSE Grantees Meeting December 2015 The Spherical Nucleic Acid (SNA) Nanoparticle Changes the Paradigm for Oligo Therapeutics Linear DNA SNA Each company limited by chemistry, modality, and tissue of interest
More informationOTCQB: XCUR. October 2018
OTCQB: XCUR October 2018 Disclaimers SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained
More informationRXi Pharmaceuticals. BioPharm America September 26, 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals BioPharm America September 26, 2017 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationNUVEC. Non-viral adjuvant delivery system for vaccines and cancer treatments. Allan Hey, Head of CMC, N4 Pharma Ltd
NUVEC Non-viral adjuvant delivery system for vaccines and cancer treatments Allan Hey, Head of CMC, N4 Pharma Ltd 1 N4 Pharma plc o Established in 2014 o Listed on Alternative Investment Market (AIM) in
More informationJefferies Healthcare Conference. June 2016
Jefferies Healthcare Conference June 2016 Forward Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationOverview of CDER Nanotechnology-related Drug Database
Overview of CDER Nanotechnology-related Drug Database Nakissa Sadrieh, Ph.D. Director, Cosmetics Staff, OCAC/CFSAN/FDA (Previously, Associate Director for Research Policy and Implementation, OPS/CDER/FDA)
More informationMarch Company Introduction. Microbiome R&D and Business Collaboration Forum: Europe Myriam Golembo, VP Development
March 2018 Company Introduction Microbiome R&D and Business Collaboration Forum: Europe Myriam Golembo, VP Development Biomx At A Glance We are a microbiome drug discovery company developing customized
More informationNanotechnology Regulation: A Proposed Roadmap
Nanotechnology Regulation: A Proposed Roadmap Lloyd L. Tran President, International Association of Nanotechnology Director California Institute of Nanotechnology What is Nanotechnology? Nanotechnology
More informationAbGn-107, an ADC Targets Gastrointestinal Tumors
AbGn-107, an ADC Targets Gastrointestinal Tumors For a Healthier Life Presented by Ron Lin Feb. 22, 2016 All Rights reserved AbGenomics International Inc. 4966 El Camino Real, Suite 200, Los Altos, CA
More informationHELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY
HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT PPD IS A PARTNER WITH PROVEN CAPABILITIES THAT SUPPORT AND ADVANCE ONCOLOGY RESEARCH
More informationNanodiamond-Based Therapeutic Delivery Films For the Treatment of Cancer and Inflammation
Nanodiamond-Based Therapeutic Delivery Films For the Treatment of Cancer and Inflammation Dean Ho, Ph.D. Assistant Professor Departments of Biomedical and Mechanical Engineering Lurie Comprehensive Cancer
More informationOncology Product and Platform Partnering Opportunity
Protein Medicinal Chemistry with an Expanded Genetic Code Oncology Product and Platform Partnering Opportunity April 2017 Ambrx has Made Advances in Proprietary Platform and Titer while Achieving Clinical
More informationPDS Biotechnology and Edge Therapeutics. Proposed Combination. November 26, A new generation of multifunctional
PDS Biotechnology and Edge Therapeutics Proposed Combination November 26, 2018 A new generation of multifunctional immunotherapies Forward-Looking Statements This presentation contains forward-looking
More informationCorporate Overview. June 2017
Corporate Overview June 2017 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included
More informationCombination Therapies. Inhibitors
Combination Therapies with Immune The Value of Partnerships Checkpoint - Case Study - Inhibitors The Value of Partnerships - Case Study - New data is forecasting that the immune checkpoint inhibitor market
More informationJan Company Introduction. Microbiome Drug Development Europe Assaf Oron, CBO
Jan. 2018 Company Introduction Microbiome Drug Development Europe Assaf Oron, CBO Biomx At A Glance We are a microbiome drug discovery company developing customized phage therapies that target and destroy
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationQ Earnings and Corporate Developments. October 31, 2018
Q3 2018 Earnings and Corporate Developments October 31, 2018 1 Intellia Therapeutics Legal Disclaimers This presentation contains forward-looking statements of Intellia Therapeutics, Inc. ( Intellia )
More informationJefferies Healthcare Conference
0 Jefferies Healthcare Conference 3 June 2015 NASDAQ: CRIS Forward Looking & Other Important Cautionary Statements This presentation contains forward-looking statements for purposes of the safe harbor
More informationCORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER
CORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER March 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements
More informationNanomaterials for Healthcare. Hans Hofstraat. hilips Research Laboratories, Eindhoven, The Netherlands
Nanomaterials for Healthcare Hans Hofstraat hilips Research Laboratories, Eindhoven, The Netherlands utline Introduction Promises of nanotechnology Nanotechnology at Philips Using nanotechnology for real
More informationNanotechnology Principles, Applications, Careers, and Education. Copyright 2011 The Pennsylvania State University
Nanotechnology Principles, Applications, Careers, and Education Copyright 2011 The Pennsylvania State University Outline What are the principles of nanotechnology? What are some applications? What kind
More informationIn Vivo Programs. Contract Research Services. Programs
P r o d u c t N o t e Contract Research Services In Vivo Programs Key Features Evaluation of drug properties Drug efficacy studies Biodistribution studies Complementary tissue analysis services CDAS In
More informationCorporate Presentation OCTOBER 2018
Corporate Presentation OCTOBER 2018 This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated
More informationGenentech Contacts: Media: Tara Cooper (650) Investor: Kathee Littrell (650)
NEWS RELEASE Genentech Contacts: Media: Tara Cooper (650) 225-5505 Investor: Kathee Littrell (650) 225-1034 XOMA Media/Investor Contacts: Laura Zobkiw (510) 204-7273 Peter Davis (510) 204-7231 FDA APPROVES
More informationEE 45X Biomedical Nanotechnology. Course Proposal
EE 45X Biomedical Nanotechnology 1 Introduction Jie Chen ECERF W6-019 492-9820 jchen@ece.ualberta.ca Oct. 15, 2008 The purpose of this document is to propose a new course in the area of Biomedical Nanotechnology
More informationREALIZING THE POWER OF RED: A NEW ERA IN CELLULAR MEDICINE
REALIZING THE POWER OF RED: A NEW ERA IN CELLULAR MEDICINE PABLO J. CAGNONI, M.D., CHIEF EXECUTIVE OFFICER JANUARY 2019 1 Forward-Looking Statements This presentation may contain forward-looking statements.
More informationSupplementary Information
1 2 Supplementary Information 3 4 5 6 7 8 Supplementary Figure 1. Loading of R837 into PLGA nanoparticles. The loading efficiency (a) and loading capacity (b) of R837 by PLGA nanoparticles obtained at
More informationQ PRESENTATION November 28, 2017 Per Walday, CEO Ronny Skuggedal, CFO
Q3 2017 PRESENTATION November 28, 2017 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationCustomized Phage Therapies To Eradicate Harmful Bacteria In Chronic Diseases. Europe Microbiome Congress London, 14 Nov., 2018
Customized Phage Therapies To Eradicate Harmful Bacteria In Chronic Diseases Europe Microbiome Congress London, 14 Nov., 2018 Biomx At A Glance We are a microbiome drug discovery company developing customized
More informationINTRODUCTION TO NANOTECHNOLOGIES AND NANOMATERIALS
INTRODUCTION TO NANOTECHNOLOGIES AND NANOMATERIALS Prof Jim Bridges Chair, Scientific Committee for Emerging and Newly Identified Health Risks (SCENIHR), and Emeritus Professor of Toxicology and Environmental
More informationDeveloping Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013
Developing Targeted Stem Cell Therapeutics for Cancer Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 The Challenge of Drug Delivery for Brain Cancer Stem Cells
More informationAdvancing the Frontiers of mab mixtures
Advancing the Frontiers of mab mixtures...unlocking the power of the immune system Symphogen Corporate Presentation June 216 Symphogen/1 Symphogen Overview Privately held company - 125 employees Headquarters
More informationAdvancing Manufacturing for Advanced Therapies
Advancing Manufacturing for Advanced Therapies Peter Marks, MD, PhD Center For Biologics Evaluation and Research, FDA CASSS Cell & Gene Therapy Symposium July 10, 2018 Overview Cell and gene therapy products
More informationPhase 1 Clinical Studies First-In-Human (FIH) <Chapter 31> Pharmacologically-Guided Dose Escalation
Phase 1 Clinical Studies First-In-Human (FIH) Pharmacologically-Guided Dose Escalation Jerry M. Collins, Ph.D. Developmental Therapeutics Program Division of Cancer Treatment and Diagnosis,
More informationExpectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products
Expectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products Approved by the IPRP Management Committee on 3 June 2018 12 April 2018 Table of Contents 1. Position Statement... 3 2. Executive
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationPrecigen Company Update
Precigen Company Update Helen Sabzevari, PhD President, Precigen 9 January 2019 JP Morgan 37 th Annual Healthcare Conference Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation
More informationFDA Regulation of Companion Diagnostics
FDA Regulation of Companion Diagnostics Paul Radensky October 11, 2017 Disclosure + Slideset drawn from Part I of presentation made by Janice Hogan, HoganLovells, October 2016 + Updated where appropriate
More informationFinancial Results FY2018 Q3
Financial Results FY2018 Q3 (January to September 2018) Carna Biosciences, Inc. Stock Code:4572 1 FY2018 Q3 Key Highlights Established the clinical development team to initiate clinical trials of Carnaʼs
More informationChapter 8 Healthcare Biotechnology
Chapter 8 Healthcare Biotechnology Outline: 8.1 Introduction 8.2 Biopharming 8.3 Models of Human Disease 8.4 Detecting and Diagnosing Human Disease 8.5 Monoclonal Antibodies 8.6 Gene Therapy 8.7 Tissue
More informationMay Microbiome Modulation. Assaf Oron, CBO Biomed Conference Tel Aviv, May 2017
May 2017 Microbiome Modulation Assaf Oron, CBO Biomed Conference Tel Aviv, May 2017 Microbiome A revolutionary cure Linda, lives in California 2010 Was treated with antibiotics due to a severe urinary
More informationDNA Coated Gold Nanoshells for Laser Induced Antisense Drug Release in Cells
DNA Coated Gold Nanoshells for Laser Induced Antisense Drug Release in Cells Marcus Rosario Mentor Gary Braun Dr. Norbert Reich National Institutes of Health Ventura College Molecular Biology The Big Picture
More informationTopical sirna for management of androgenic alopecia and oily skin Quark Pharmaceuticals, Inc.
Topical sirna for management of androgenic alopecia and oily skin 1 2017 Quark Pharmaceuticals, Inc. About Quark Founded in 1993; privately held Late stage pharmaceutical company with 2 Phase 3 programs,
More informationDiscovery of a First-In-Class Topically Bioavailable Kit Inhibitor With Clinical Activity Using Computational Chemogenomics Technology
20131009-03 Discovery of a First-In-Class Topically Bioavailable Kit Inhibitor With Clinical Activity Using Computational Chemogenomics Technology James Hendrix, Ph.D. President - Technology Med Chem &
More informationSupplementary Figure 1. CryoTEM images of the barcoded nanoparticles (a) and
a b Supplementary Figure 1. CryoTEM images of the barcoded nanoparticles (a) and size measurements of the particles (b). Liposomes were loaded with DNA barcodes and were imaged using cryo-tem and measured
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationWhat is an Aptamer? smallest unit of repeating structure
What is an Aptamer? apto: mer: to fit smallest unit of repeating structure Aptamers are single stranded folded oligonucleotides that bind to molecular (protein) targets with high affinity and specificity
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationThe Application of DNA Nanotechnology for Guided Drug Delivery
Tony Wang Professor Scarlatos HON 301 October 19th, 2014 Introduction: The Application of DNA Nanotechnology for Guided Drug Delivery A major problem that exists in drug-based disease treatments is the
More informationNanoAssemblr Benchtop. Develop Future Nanomedicines
NanoAssemblr Benchtop Develop Future Nanomedicines Develop the Future of Medicine Overcome key challenges in advancing nanomedicines: Challenges with conventional production methods Solutions with the
More informationExpression Profiling for
RNAi Screen, NGS and Expression Profiling for Biomarker Discovery Namjin Chung Applied Genomics Bristol-Myers Squibb 2012 DOT Oct 2, 2012 Boston, MA Pharmacogenomics Study of the role of inheritance in
More informationNanosensors. Rachel Heil 12/7/07 Wentworth Institute of Technology Department of Electronics and Mechanical Professor Khabari Ph.D.
Nanosensors Rachel Heil 12/7/07 Wentworth Institute of Technology Department of Electronics and Mechanical Professor Khabari Ph.D. There are many advances in nanotechnology that if perfected could help
More informationUniversity of California Center for Accelerated Innovation
University of California Center for Accelerated Innovation MICHAEL PALAZZOLO April 6, 2015 Outline CAI overview and introduction RFA and important dates Selection process Pre-application Finding help 2
More information2.3 Quantum Dots (QDs)
2.3 Quantum Dots (QDs) QDs are inorganic nanocrystals, approximately 1 10 nm in size, with unique optical properties of broad excitation, narrow size-tunable emission spectra, high photochemical stability,
More informationNANOONCOLOGY: DRUG DELIVERY IN NEUROLOGICAL CANCERS. By Ian Kanterman BME281
NANOONCOLOGY: DRUG DELIVERY IN NEUROLOGICAL CANCERS By Ian Kanterman BME281 Introduction Nanooncology is the application of Nanomedicine to cancer diagnosis and treatment. Has the potential to alter clinical
More informationDevelopment of differentiated immuno-oncology therapeutics by using multivalent Nanobodies
Nanobodies Innovative therapeutics Development of differentiated immuno-oncology therapeutics by using multivalent Nanobodies Immune Checkpoint Inhibitors Europe Sandra Li - 17 November 2016 Forward looking
More informationPartnering for Impact Human Health Therapeutics
Partnering for Impact Human Health Therapeutics Bernard Massie General Manager Human Health Therapeutics Partnering for Impact in Biologics and Vaccines NRC s Human Health Therapeutics (HHT) portfolio
More informationNonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
More informationAffinity Reagents: The Landscape and Affimer Technology Competitive Advantages
Affinity Reagents: The Landscape and Affimer Technology Competitive Advantages Introduction It is well accepted that the limitations of antibodies present valuable commercial opportunities for alternative
More informationPHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA JOSHUA RICHTER 1 ; OLA LANDGREN 2 ; JOHN KAUH 3 ; JONATHAN BACK
More informationGene therapy has gained significant attention over the past two decades as a potential method for treating genetic disorders such as severe combined
Abstract Gene therapy has gained significant attention over the past two decades as a potential method for treating genetic disorders such as severe combined immunodeficiency, cystic fibrosis, and Parkinson
More informationPioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination.
Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination. Founded 1999, Clague Hodgson, Ph.D. Chief Scientific Officer, VP, R&D, Jim Williams,
More informationNIA Open Webinar Nanomedicine: Diagnostics and therapeutics advancing through nanotechnology
NIA Open Webinar Nanomedicine: Diagnostics and therapeutics advancing through nanotechnology 7 March 2018 1500 CET The webinar will start at 1500 CET and we will keep participants on mute during the presentations
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More informationImmune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 1, 2017 Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01,
More informationQ4 & Interim Full Year 2018 PRESENTATION February 13, 2019 Per Walday, CEO Ronny Skuggedal, CFO
Q4 & Interim Full Year 2018 PRESENTATION February 13, 2019 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements
More informationQuantitative And Spatial Optimization Of Therapeutic Fusion Proteins
Quantitative And Spatial Optimization Of Therapeutic Fusion Proteins Jeffrey Way, Ph.D. Senior Staff Scientist, Wyss Institute, HMS CEO, General Biologics, Inc. 1 Chimeric Activators Drug design and targeted
More information2/27/2010. What is Nano? SCI 102 SANYAL. Nanoscale = billionths (10-9 ) 10 billion components 8 inch diameter. 6 billion people 8000 mile diameter
What is Nano? SANYAL SCI 102 Nanoscale = billionths (10-9 ) 6 billion people 8000 mile diameter 10 billion components 8 inch diameter 1 Nano in Therapeutics Drugs: up to ~10 nm Example: Insulin Surgery:
More informationCurrent developments in China on the safety of. manufactured nanomaterials
Current developments in China on the safety of manufactured nanomaterials Abstract In our report we collected information on the following initiatives related to the safety of nanomaterials in China after
More informationInstructor: Laboratory Location: Contact Information: Website: Course Information: Research Interests: Instructor: Laboratory Location:
Exciting Research Opportunities For Undergraduate Honors Students At The University of Toledo College of Medicine and Life Sciences!!! Please see the list of faculty and research interests below for exciting
More information7/24/2014. Scientifically driven proof of principle trials: Current and future value to drug development. Disclosure Information
July 24, 2014 Scientifically driven proof of principle trials: Current and future value to drug development Elizabeth M. Jaffee, M.D. Dana and Albert Broccoli Professor of Oncology Skip Viragh Pancreatic
More informationNanotechnologie in der Lebensmittelindustrie
Nanotechnologie in der Lebensmittelindustrie Peter Schurtenberger Department of Physics and Fribourg Center for Nanomaterials (FriMat) University of Fribourg 1700 Fribourg, Switzerland www.unifr.ch/physics/mm/
More informationQuantum Dots and Carbon Nanotubes in Cancer diagnose EE453 Project Report submitted by Makram Abd El Qader
Quantum Dots and Carbon Nanotubes in Cancer diagnose EE453 Project Report submitted by Makram Abd El Qader abdelqad@unlv.nevada.edu, Fall 2008 Abstract On the basis of research and cancer medical treatment,
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationREDX PHARMA PLC ( Redx or Company or Group ) Interim Results
24 May 2016 AIM: REDX REDX PHARMA PLC ( Redx or Company or Group ) Interim Results Redx (AIM: REDX), the drug discovery and development company, is pleased to announce its unaudited interim results for
More informationNanotechnology & UIC (Engineering & Science)
Nanotechnology & Nanobiotechnology @ UIC (Engineering & Science) by G.Ali Mansoori, PhD mansoori@uic.edu BioEngineering, Chemical Engineering & Physics Departments at Livingston Nanotechnology Conference
More informationChapter 18. Viral Genetics. AP Biology
Chapter 18. Viral Genetics AP Biology What is a virus? Is it alive? DNA or RNA enclosed in a protein coat Viruses are not cells Extremely tiny electron microscope size smaller than ribosomes ~20 50 nm
More informationStifel Nicolaus Healthcare Conference. September 2012
Stifel Nicolaus Healthcare Conference September 212 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of
More informationFDA Perspectives on Biomarkers. Steven Kozlowski, M.D. Office of Biotechnology Products OPS/CDER/FDA
FDA Perspectives on Biomarkers Steven Kozlowski, M.D. Office of Biotechnology Products OPS/CDER/FDA Importance of Biomarkers Earlier diagnosis Focusing expensive & invasive therapies on the right populations
More informationAn Update on the Development of sd-rxrna for Retinoblastoma Therapy
NASDAQ: RXII An Update on the Development of sd-rxrna for Retinoblastoma Therapy Next Generation in RNAi Michael Byrne, PhD ARVO May 8, 214 2 Forward Looking Statements This presentation contains forward-looking
More informationINNOVATION ALMOST 180 MILLION EUROS AREAS OF INNOVATION
From health to beauty INNOVATION IMAGINING FUTURE PRODUCTS 40 Investments in R&D reflect the importance that we attach to the discovery and development of innovative therapeutic and well-being solutions,
More informationMarina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics
Marina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics CAMBRIDGE, MA, August 14, 2013 Marina Biotech, Inc. (OTC Pink: MRNA): Assigns Unlocked Nucleobase
More informationSo What Is Nanotechnology
So What Is Nanotechnology Science of Technology 2011 Project Lead The Way, Inc. What Is Nanotechnology? Nanotechnology allows the manipulation of atoms or molecules to create or modify materials at the
More informationPrinciples of translational medicine: imaging, biomarker imaging, theranostics
Principles of translational medicine: imaging, biomarker imaging, theranostics Compiled by: Endre Mikus PhD, CEO Budapest, 21/9/2015 Imaging and imaging biomarkers An imaging biomarker is an anatomic,
More informationImmuno-Oncology Program
Immuno-Oncology Program 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
More informationSynthetic Viruses Targeting Cancer
Synthetic Viruses Targeting Cancer Andrew Hessel September 7, 2007 SENS 3, Cambridge, UK Why is a new strategy necessary? Breast cancer remains a significant cause of illness and death The treatment options
More informationA pre-clinical PKPD framework for biomarker led decision making for prioritising dose and schedules for anti-cancer agents to test in the clinic
A pre-clinical PKPD framework for biomarker led decision making for prioritising dose and schedules for anti-cancer agents to test in the clinic Rhys D Owen Jones, Oncology imed 1st International Workshop
More informationBEH.462/3.962J Molecular Principles of Biomaterials Spring 2003
Lecture 17: Drug targeting Last time: Today: Intracellular drug delivery Drug targeting Reading: T.J. Wickham, Ligand-directed targeting of genes to the site of disease, Nat. Med. 9(1) 135-139 (2003) Drug
More informationN4 Pharma Investor Presentation
N4 Pharma Investor Presentation November 2017 Introduction o Established in 2014 o Specialist pharmaceutical company with two divisions: o Reformulation of existing generic drugs and o Silica nanoparticle
More informationCEOCFO Magazine. Dr. Jakub Staszak-Jirkovsky Co-Founder and Chief Executive Officer. Machavert Pharmaceuticals
CEOCFO Magazine ceocfointerviews.com All rights reserved Issue: February 11, 2019 Developing the first Drug Candidates based on Phospholipid that Activates Natural Killer Cells, Machavert Pharmaceuticals
More informationImmunotherapy in myeloma
Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to
More informationFDA Perspective on the Preclinical Development of Cancer Vaccines
FDA Perspective on the Preclinical Development of Cancer Vaccines Richard D. McFarland Ph.D., M.D. Medical Officer CBER/OCTGT/DCEPT mcfarlandr@cber.fda.gov Cancer Vaccine Clinical Trials Workshop Alexandria,
More informationCRITERIA FOR PROJECT SELECTION
CRITERIA FOR PROJECT SELECTION The CITN is a network of eperienced immunotherapy investigators with inherently diverse research interests. Thus, we have established guidelines to epedite project selection
More information